Answer
In patients with existing cardiovascular risk factors, factor VIII replacement therapy with ALTUVOCT (efanesoctocog alfa) may increase cardiovascular risk.
Sources for this answer
- ALTUVOCT 1 000 IU powder and solvent for solution for injectionSwedish Orphan Biovitrum Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 3Document updated
Sources checked